CAS Number188062-50-2
SynonymsMFCD04112763; (1S,4R)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol; {(1S,4R)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopenten-1-yl}methyl hydrogen sulfate; Abacavir sulfate; Abacavir (sulfate)
Molecular FormulaC28H38N12O6S
Molecular Weight670.74
Density1.9±0.1 g/cm3
Boiling Point636ºC at 760 mmHg
Melting Point222-225ºC
AppearanceWhite to off-white solid
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 188062-50-2 |
| Catalog No. | 2A-1170857 |
| Chinese Name | 硫酸阿巴卡韦 |
| Synonyms | MFCD04112763; (1S,4R)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol; {(1S,4R)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopenten-1-yl}methyl hydrogen sulfate; Abacavir sulfate; Abacavir (sulfate) |
| Molecular Formula | C28H38N12O6S |
| Molecular Weight | 670.74 |
| Density | 1.9±0.1 g/cm3 |
| Boiling Point | 636ºC at 760 mmHg |
| Melting Point | 222-225ºC |
| Appearance | White to off-white solid |
| Storage Condition | -20°C Freezer |
| Application | Abacavir (ABC) sulfate is a nucleoside analog reverse transcriptase inhibitor (NRTI) used for HIV and AIDS. |
| PubChem ID | 7847955 |
| SMILES | Nc1nc(NC2CC2)c2ncn(C3C=CC(CO)C3)c2n1.O=S(=O)(O)O |
| InChI | InChI=1S/2C14H18N6O.H2O4S/c2*15-14-18-12(17-9-2-3-9)11-13(19-14)20(7-16-11)10-4-1-8(5-10)6-21;1-5(2,3)4/h2*1,4,7-10,21H,2-3,5-6H2,(H3,15,17,18,19);(H2,1,2,3,4)/t2*8-,10+;/m11./s1 |
| InChI Key | MBFKCGGQTYQTLR-SCYNACPDSA-N |
| Bioactivity | Abacavir sulfate (ABC) is a powerful nucleoside analog reverse transcriptase inhibitor (NRTI) used to treat HIV and AIDS. Target: NRTIAbacavir is a nucleoside reverse transcriptase inhibitor marketed since 1999 for the treatment of infection with the human immunodeficiency virus type 1 (HIV). Despite its clinical efficacy, abacavir administration has been associated with serious and sometimes fatal toxic events. Abacavir has been reported to undergo bioactivation in vitro, yielding reactive species that bind covalently to human serum albumin, but the haptenation mechanism and its significance to the toxic events induced by this anti-HIV drug have yet to be elucidated. The mechanism underlying abacavir hypersensitivity syndrome is related to the change in the HLA-B*5701 protein product. Abacavir binds with high specificity to the HLA-B*5701 protein, changing the shape and chemistry of the antigen-binding cleft. This results in a change in immunological tolerance and the subsequent activation of abacavir-specific cytotoxic T cells, which produce a systemic reaction known as abacavir hypersensitivity syndrome. Related Catalog Signaling Pathways >> Anti-infection >> Reverse Transcriptase Research Areas >> Infection References [1]. Charneira C, et al. Reactive aldehyde metabolites from the anti-HIV drug abacavir: amino acid adducts as possible factors in abacavir toxicity. Chem Res Toxicol. 2011 Dec 19;24(12):2129-41. [2]. Hervey PS, et al. Abacavir: a review of its clinical potential in patients with HIV infection. Drugs. 2000 Aug;60(2):447-79. Chemical & Physical Properties Density 1.9±0.1 g/cm3 Boiling Point 636ºC at 760 mmHg Melting Point 222-225ºC Molecular Formula C28H38N12O6S Molecular Weight 670.74 Flash Point 338.4ºC PSA 153.63000 LogP 0.74 Index of Refraction 1.851 InChIKey MBFKCGGQTYQTLR-SCYNACPDSA-N SMILES Nc1nc(NC2CC2)c2ncn(C3C=CC(CO)C3)c2n1.O=S(=O)(O)O Storage condition -20°C Freezer |
| Use of | Abacavir sulfate (ABC) is a powerful nucleoside analog reverse transcriptase inhibitor (NRTI) used to treat HIV and AIDS. Target: NRTIAbacavir is a nucleoside reverse transcriptase inhibitor marketed since 1999 for the treatment of infection with the human immunodeficiency virus type 1 (HIV). Despite its clinical efficacy, abacavir administration has been associated with serious and sometimes fatal toxic events. Abacavir has been reported to undergo bioactivation in vitro, yielding reactive species that bind covalently to human serum albumin, but the haptenation mechanism and its significance to the toxic events induced by this anti-HIV drug have yet to be elucidated. The mechanism underlying abacavir hypersensitivity syndrome is related to the change in the HLA-B*5701 protein product. Abacavir binds with high specificity to the HLA-B*5701 protein, changing the shape and chemistry of the antigen-binding cleft. This results in a change in immunological tolerance and the subsequent activation of abacavir-specific cytotoxic T cells, which produce a systemic reaction known as abacavir hypersensitivity syndrome. Properties Name abacavir sulfate Synonym More Synonyms Abacavir Sulfate Biological Activity Description Abacavir sulfate (ABC) is a powerful nucleoside analog reverse transcriptase inhibitor (NRTI) used to treat HIV and AIDS. Target: NRTIAbacavir is a nucleoside reverse transcriptase inhibitor marketed since 1999 for the treatment of infection with the human immunodeficiency virus type 1 (HIV). Despite its clinical efficacy, abacavir administration has been associated with serious and sometimes fatal toxic events. Abacavir has been reported to undergo bioactivation in vitro, yielding reactive species that bind covalently to human serum albumin, but the haptenation mechanism and its significance to the toxic events induced by this anti-HIV drug have yet to be elucidated. The mechanism underlying abacavir hypersensitivity syndrome is related to the change in the HLA-B*5701 protein product. Abacavir binds with high specificity to the HLA-B*5701 protein, changing the shape and chemistry of the antigen-binding cleft. This results in a change in immunological tolerance and the subsequent activation of abacavir-specific cytotoxic T cells, which produce a systemic reaction known as abacavir hypersensitivity syndrome. Related Catalog Signaling Pathways >> Anti-infection >> Reverse Transcriptase Research Areas >> Infection References [1]. Charneira C, et al. Reactive aldehyde metabolites from the anti-HIV drug abacavir: amino acid adducts as possible factors in abacavir toxicity. Chem Res Toxicol. 2011 Dec 19;24(12):2129-41. [2]. Hervey PS, et al. Abacavir: a review of its clinical potential in patients with HIV infection. Drugs. 2000 Aug;60(2):447-79. Chemical & Physical Properties Molecular Formula C28H38N12O6S PSA 153.63000 Index of Refraction 1.851 InChIKey MBFKCGGQTYQTLR-SCYNACPDSA-N |
| Transport Info | Product name: Abacavir sulfate |
| Related Products in API & Advanced Intermediates | ||
|---|---|---|
| Norfloxacin Lactate Injection | 2A-1170770 | 2A-1170770 |
| Ganciclovir Mono-O-acetate | 88110-89-8 | 2A-1170805 |
| ATORVASTATIN SODIUM | 134523-01-6 | 2A-1170827 |
| 2-Desethyl-2-propylazithromycin | 763924-54-5 | 2A-1170837 |
| trans-Abacavir Hydrochloride | 267668-71-3 | 2A-1170856 |
| Abacavir Carboxylate | 384380-52-3 | 2A-1170858 |
| Abacavir 5'-Glucuronide | 384329-76-4 | 2A-1170859 |
| Abacavir 5’-Phosphate | 136470-77-4 | 2A-1170860 |
| Anhydro Abiraterone | 154229-20-6 | 2A-1170886 |
| Abiraterone Related CoMpound 2 (Prasterone Triflate) | 124643-35-2 | 2A-1170887 |
| Browse all API & Advanced Intermediates products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS